Dr. Eric van der Veer (CSO & founder) joined the Leiden University Medical Center (LUMC) as post-doc fellow in 2007. During his extensive research period (2007-2015) he focused mainly on RNA-based therapies. Due to his many successful publications, he was asked to become Assistant Professor at Leiden University. In October 2015, he came up with the idea to combine his knowledge on RNA with anti-viral therapies and the concept of Hybridize Therapeutics was born. In September 2019, Dr. Eric van der Veer decided to create a spin-off out of the LUMC and officially founded Hybridize Therapeutics. Currently, Hybridize Therapeutics is in the pre-clinical phase for our therapy against BK-virus and in the early pre-clinical phase for our therapy against SARS-CoV2 & JC-virus
Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.